AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Madrigal Pharmaceuticals, Inc.
Video analysis: MDGL
All videosNo video analysis for this stock yet. Request one from our team.
News: MDGL
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You?
Madrigal's only commercial drug, Rezdiffra, continues to grow sales. Institutional investors hold more than 95% of the stock's float.
Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference
CONSHOHOCKEN, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that the company will participate in the 2026 Cantor Global Healthcare Conference on Thursday, Sept.
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Consensus Rating of “Moderate Buy” by Analysts
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL - Get Free Report) has earned an average recommendation of "Moderate Buy" from the eighteen research firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and fifteen have issued a buy rating on the
Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off
MASH cirrhosis could significantly expand Rezdiffra's addressable market. Madrigal's developing pipeline could reduce its dependence on Rezdiffra.
Allworth Financial LP Buys New Position in Madrigal Pharmaceuticals, Inc. $MDGL
Allworth Financial LP bought a new position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) in the second quarter, according to the company in its most recent filing with the SEC. The fund bought 3,562 shares of the biopharmaceutical company's stock, valued at approximately $1,913,000. Several other hedge funds and other institutional investors
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on August 15, 2026 to 13 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands
Madrigal Pharmaceuticals (NASDAQ: MDGL) said Rezdiffra continued to post strong commercial growth in the second quarter of 2026, while the company expanded its development pipeline around the MASH therapy and prepared for several potential clinical catalysts. Speaking at a Canaccord Genuity event, Chief Financial Officer Mardi Dier said the company reported $364 million in second-quarter revenue,
